GSK logo

GSK plc (GSK) EBITDA

Annual EBITDA:

$9.11B-$2.19B(-19.36%)
December 31, 2024

Summary

  • As of today, GSK annual EBITDA is $9.11 billion, with the most recent change of -$2.19 billion (-19.36%) on December 31, 2024.
  • During the last 3 years, GSK annual EBITDA has risen by +$192.00 million (+2.15%).
  • GSK annual EBITDA is now -53.74% below its all-time high of $19.70 billion, reached on December 31, 2015.

Performance

GSK EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherGSKincome statement metrics

Quarterly EBITDA:

$4.46B+$624.05M(+16.26%)
September 1, 2025

Summary

  • As of today, GSK quarterly EBITDA is $4.46 billion, with the most recent change of +$624.05 million (+16.26%) on September 1, 2025.
  • Over the past year, GSK quarterly EBITDA has increased by +$2.61 billion (+140.50%).
  • GSK quarterly EBITDA is now -9.38% below its all-time high of $4.92 billion, reached on September 30, 2011.

Performance

GSK Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherGSKincome statement metrics

TTM EBITDA:

$14.54B+$2.61B(+21.83%)
September 1, 2025

Summary

  • As of today, GSK TTM EBITDA is $14.54 billion, with the most recent change of +$2.61 billion (+21.83%) on September 1, 2025.
  • Over the past year, GSK TTM EBITDA has increased by +$3.09 billion (+27.01%).
  • GSK TTM EBITDA is now -18.41% below its all-time high of $17.83 billion, reached on June 30, 2008.

Performance

GSK TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherGSKincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

GSK EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-19.4%+140.5%+27.0%
3Y3 Years+2.1%+10.3%+30.7%
5Y5 Years-24.3%+17.9%+55.7%

GSK EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-19.4%+2.1%at high+290.5%at high+41.6%
5Y5-Year-24.3%+2.1%at high+290.5%at high+55.7%
All-TimeAll-Time-53.7%>+9999.0%-9.4%+179.8%-18.4%+5904.4%

GSK EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
$4.46B(+16.3%)
$14.54B(+21.8%)
Jun 2025
-
$3.84B(+2.9%)
$11.94B(+4.6%)
Mar 2025
-
$3.73B(+48.3%)
$11.41B(+4.8%)
Dec 2024
$9.11B(-19.4%)
$2.52B(+35.6%)
$10.89B(-4.9%)
Sep 2024
-
$1.86B(-44.0%)
$11.45B(-13.0%)
Jun 2024
-
$3.31B(+3.1%)
$13.17B(+5.1%)
Mar 2024
-
$3.21B(+4.4%)
$12.54B(+2.7%)
Dec 2023
$11.30B(+6.1%)
$3.08B(-13.9%)
$12.20B(+18.8%)
Sep 2023
-
$3.57B(+33.4%)
$10.27B(-4.4%)
Jun 2023
-
$2.68B(-7.0%)
$10.74B(-0.9%)
Mar 2023
-
$2.88B(+152.0%)
$10.84B(+1.6%)
Dec 2022
$10.65B(+19.4%)
$1.14B(-71.8%)
$10.67B(-4.1%)
Sep 2022
-
$4.05B(+45.9%)
$11.13B(+5.4%)
Jun 2022
-
$2.77B(+2.2%)
$10.56B(+0.8%)
Mar 2022
-
$2.71B(+69.4%)
$10.48B(+1.4%)
Dec 2021
$8.92B(-13.8%)
$1.60B(-53.9%)
$10.33B(-13.3%)
Sep 2021
-
$3.47B(+29.3%)
$11.92B(-2.5%)
Jun 2021
-
$2.69B(+4.5%)
$12.22B(+25.3%)
Mar 2021
-
$2.57B(-19.2%)
$9.75B(-5.6%)
Dec 2020
$10.35B(-14.0%)
$3.18B(-15.9%)
$10.33B(+10.6%)
Sep 2020
-
$3.78B(+1661.8%)
$9.34B(+4.4%)
Jun 2020
-
$214.81M(-93.2%)
$8.95B(-25.5%)
Mar 2020
-
$3.15B(+43.5%)
$12.02B(-6.0%)
Dec 2019
$12.05B(+22.8%)
$2.19B(-35.3%)
$12.79B(-4.6%)
Sep 2019
-
$3.39B(+3.3%)
$13.41B(+1.6%)
Jun 2019
-
$3.28B(-16.2%)
$13.20B(+6.6%)
Mar 2019
-
$3.92B(+39.0%)
$12.38B(+8.8%)
Dec 2018
$9.81B(+22.8%)
$2.82B(-11.2%)
$11.37B(-1.1%)
Sep 2018
-
$3.18B(+28.9%)
$11.50B(-1.0%)
Jun 2018
-
$2.46B(-15.4%)
$11.62B(-2.4%)
Mar 2018
-
$2.91B(-1.2%)
$11.91B(+6.3%)
Dec 2017
$7.98B(+33.0%)
$2.95B(-10.5%)
$11.21B(+4.6%)
Sep 2017
-
$3.30B(+19.8%)
$10.72B(+6.8%)
Jun 2017
-
$2.75B(+24.4%)
$10.04B(-1.1%)
Mar 2017
-
$2.21B(-9.9%)
$10.14B(-4.3%)
Dec 2016
$6.00B(-69.5%)
$2.46B(-6.1%)
$10.60B(+29.4%)
Sep 2016
-
$2.62B(-8.5%)
$8.19B(+3.7%)
Jun 2016
-
$2.86B(+7.0%)
$7.90B(-0.7%)
Mar 2016
-
$2.67B(+5768.5%)
$7.96B(+6.1%)
Dec 2015
$19.70B(+131.8%)
$45.50M(-98.0%)
$7.50B(-32.2%)
Sep 2015
-
$2.33B(-20.3%)
$11.05B(-8.7%)
Jun 2015
-
$2.92B(+31.8%)
$12.11B(+2.4%)
Mar 2015
-
$2.21B(-38.6%)
$11.83B(-7.0%)
Dec 2014
$8.50B(-38.3%)
$3.60B(+6.6%)
$12.71B(+51.0%)
Sep 2014
-
$3.38B(+28.2%)
$8.42B(-6.6%)
Jun 2014
-
$2.64B(-14.9%)
$9.02B(-8.7%)
Mar 2014
-
$3.10B(+549.2%)
$9.88B(-3.6%)
Dec 2013
$13.77B(-1.3%)
-$689.39M(-117.3%)
$10.25B(-33.2%)
Sep 2013
-
$3.98B(+13.9%)
$15.35B(+5.7%)
Jun 2013
-
$3.49B(+0.6%)
$14.53B(+0.1%)
Mar 2013
-
$3.47B(-21.4%)
$14.51B(+2.1%)
Dec 2012
$13.95B(-11.9%)
$4.41B(+39.9%)
$14.21B(+39.4%)
Sep 2012
-
$3.15B(-9.1%)
$10.20B(-14.8%)
Jun 2012
-
$3.47B(+9.4%)
$11.97B(-3.2%)
Mar 2012
-
$3.17B(+700.1%)
$12.36B(-0.0%)
Dec 2011
$15.84B(+82.8%)
$396.66M(-91.9%)
$12.36B(+24.9%)
Sep 2011
-
$4.92B(+27.3%)
$9.90B(+13.0%)
Jun 2011
-
$3.87B(+21.7%)
$8.76B(+58.1%)
Mar 2011
-
$3.18B(+253.5%)
$5.54B(-7.9%)
Dec 2010
$8.67B(-46.0%)
-$2.07B(-154.6%)
$6.02B(-48.1%)
Sep 2010
-
$3.79B(+487.3%)
$11.60B(-2.6%)
Jun 2010
-
$645.08M(-82.3%)
$11.90B(-17.2%)
Mar 2010
-
$3.65B(+4.1%)
$14.38B(+0.2%)
Dec 2009
$16.03B(-0.7%)
$3.51B(-14.3%)
$14.34B(+0.9%)
Sep 2009
-
$4.09B(+31.2%)
$14.22B(+30.9%)
Jun 2009
-
$3.12B(-13.8%)
$10.86B(-10.3%)
Mar 2009
-
$3.62B(+7.0%)
$12.10B(-5.8%)
Dec 2008
$16.15B(-12.5%)
$3.38B(+359.6%)
$12.85B(-8.3%)
Sep 2008
-
$735.66M(-83.1%)
$14.01B(-21.4%)
Jun 2008
-
$4.37B(-0.1%)
$17.83B(+1.3%)
Mar 2008
-
$4.37B(-3.7%)
$17.60B(+0.0%)
Dec 2007
$18.46B(+14.3%)
$4.54B(-0.4%)
$17.59B(+8.5%)
Sep 2007
-
$4.56B(+10.1%)
$16.22B(+2.1%)
Jun 2007
-
$4.14B(-5.2%)
$15.88B(+0.4%)
Mar 2007
-
$4.36B(+37.8%)
$15.82B(+1.8%)
Dec 2006
$16.16B(+600.6%)
$3.17B(-24.9%)
$15.55B(-0.5%)
Sep 2006
-
$4.22B(+3.5%)
$15.63B(+6.4%)
Jun 2006
-
$4.07B(-0.4%)
$14.69B(+2.9%)
Mar 2006
-
$4.09B(+26.0%)
$14.28B(+5.8%)
Dec 2005
$2.31B
$3.25B(-0.9%)
$13.49B(+9.9%)
Sep 2005
-
$3.28B(-10.4%)
$12.28B(+0.2%)
DateAnnualQuarterlyTTM
Jun 2005
-
$3.66B(+10.8%)
$12.25B(+4.3%)
Mar 2005
-
$3.30B(+62.6%)
$11.75B(-0.1%)
Dec 2004
$12.12B(+2.3%)
$2.03B(-37.6%)
$11.77B(-12.3%)
Sep 2004
-
$3.26B(+3.1%)
$13.42B(-1.0%)
Jun 2004
-
$3.16B(-4.9%)
$13.56B(-1.3%)
Mar 2004
-
$3.32B(-10.1%)
$13.73B(+1.4%)
Dec 2003
$11.84B(+20.6%)
$3.69B(+8.8%)
$13.54B(+5.4%)
Sep 2003
-
$3.39B(+1.8%)
$12.85B(+7.1%)
Jun 2003
-
$3.33B(+6.6%)
$12.00B(+6.1%)
Mar 2003
-
$3.13B(+4.2%)
$11.31B(+6.8%)
Dec 2002
$9.82B(-1.4%)
$3.00B(+18.1%)
$10.59B(-0.8%)
Sep 2002
-
$2.54B(-3.7%)
$10.68B(+2.6%)
Jun 2002
-
$2.64B(+9.6%)
$10.41B(+3.0%)
Mar 2002
-
$2.41B(-22.1%)
$10.11B(+6.8%)
Dec 2001
$9.96B(-7.5%)
$3.09B(+36.1%)
$9.46B(-8.5%)
Sep 2001
-
$2.27B(-2.9%)
$10.34B(+6.3%)
Jun 2001
-
$2.34B(+32.5%)
$9.73B(+3.6%)
Mar 2001
-
$1.77B(-55.5%)
$9.40B(-4.1%)
Dec 2000
$10.77B(+107.5%)
$3.97B(+138.9%)
$9.80B(+3945.8%)
Sep 2000
-
$1.66B(-17.2%)
$242.24M(-89.1%)
Jun 2000
-
$2.00B(-7.6%)
$2.23B(+53.9%)
Mar 2000
-
$2.17B(+138.8%)
$1.45B(-43.6%)
Dec 1999
$5.19B(-3.0%)
-$5.59B(-253.4%)
$2.57B(-16.0%)
Sep 1999
-
$3.65B(+197.7%)
$3.05B(+8.8%)
Jun 1999
-
$1.22B(-62.7%)
$2.81B(+2.5%)
Mar 1999
-
$3.29B(+164.4%)
$2.74B(+4.1%)
Dec 1998
$5.36B(-0.5%)
-$5.11B(-250.1%)
$2.63B(+10.6%)
Sep 1998
-
$3.40B(+194.3%)
$2.38B(+6.6%)
Jun 1998
-
$1.16B(-63.7%)
$2.23B(-48.9%)
Mar 1998
-
$3.18B(+159.3%)
$4.37B(-3.5%)
Dec 1997
$5.38B(-5.6%)
-$5.36B(-264.7%)
$4.53B(-35.7%)
Sep 1997
-
$3.25B(-1.1%)
$7.04B(-8.0%)
Jun 1997
-
$3.29B(-1.4%)
$7.65B(+1.4%)
Mar 1997
-
$3.34B(+217.3%)
$7.55B(+1.1%)
Dec 1996
$5.70B(+10.9%)
-$2.85B(-173.6%)
$7.47B(-27.6%)
Sep 1996
-
$3.87B(+21.3%)
$10.31B(+14.5%)
Jun 1996
-
$3.19B(-2.1%)
$9.01B(+1745.6%)
Mar 1996
-
$3.26B(+27.0%)
$488.17M(-79.4%)
Dec 1995
$5.14B(+58.9%)
-
-
Sep 1995
-
$2.56B(+148.1%)
$2.37B(+1.4%)
Jun 1995
-
-$5.33B(-310.9%)
$2.34B(-41.0%)
Mar 1995
-
$2.53B(-3.3%)
$3.97B(+7.2%)
Dec 1994
-
$2.61B(+3.3%)
$3.70B(+15.4%)
Sep 1994
-
$2.53B(+168.3%)
$3.21B(+15.8%)
Jun 1994
$3.23B(+1.7%)
-$3.71B(-263.9%)
$2.77B(-14.6%)
Mar 1994
-
$2.26B(+6.6%)
$3.24B(+1.0%)
Dec 1993
-
$2.12B(+1.3%)
$3.21B(+10.8%)
Sep 1993
-
$2.09B(+164.8%)
$2.90B(+8.7%)
Jun 1993
$3.18B(+7.5%)
-$3.23B(-245.0%)
$2.66B(+5.8%)
Mar 1993
-
$2.23B(+23.3%)
$2.52B(+10.9%)
Dec 1992
-
$1.81B(-2.9%)
$2.27B(-1.8%)
Sep 1992
-
$1.86B(+155.1%)
$2.31B(-0.5%)
Jun 1992
$2.96B(+5.6%)
-$3.38B(-270.5%)
$2.33B(-41.3%)
Mar 1992
-
$1.98B(+7.2%)
$3.96B(+13.4%)
Dec 1991
-
$1.85B(-1.3%)
$3.49B(+15.1%)
Sep 1991
-
$1.87B(+207.3%)
$3.03B(+19.9%)
Jun 1991
$2.80B(+27.6%)
-$1.75B(-215.4%)
$2.53B(-0.9%)
Mar 1991
-
$1.51B(+8.7%)
$2.55B(+9.2%)
Dec 1990
-
$1.39B(+1.5%)
$2.34B(+9.3%)
Sep 1990
-
$1.37B(+179.5%)
$2.14B(+9.4%)
Jun 1990
$2.19B(+13.6%)
-$1.72B(-232.7%)
$1.96B(-20.5%)
Mar 1990
-
$1.30B(+8.8%)
$2.46B(+12.8%)
Dec 1989
-
$1.19B(+0.5%)
$2.18B(+9.3%)
Sep 1989
-
$1.19B(+197.3%)
$1.99B(+9.3%)
Jun 1989
$1.93B(+18.9%)
-$1.22B(-219.8%)
$1.82B(-9.2%)
Mar 1989
-
$1.02B(+1.1%)
$2.01B(+8.3%)
Dec 1988
-
$1.01B(-1.1%)
$1.85B(+11.6%)
Sep 1988
-
$1.02B(+198.4%)
$1.66B(+10.4%)
Jun 1988
$1.62B(+31.1%)
-$1.03B(-219.8%)
$1.51B(-10.5%)
Mar 1988
-
$863.72M(+6.1%)
$1.68B(+9.7%)
Dec 1987
-
$814.42M(-5.5%)
$1.53B(+13.5%)
Sep 1987
-
$862.23M(+200.4%)
$1.35B(+16.3%)
Jun 1987
$1.24B(+30.1%)
-$858.44M(-220.2%)
$1.16B(-7.3%)
Mar 1987
-
$714.30M(+12.9%)
$1.25B(+15.9%)
Dec 1986
-
$632.59M(-6.0%)
$1.08B(+8.4%)
Sep 1986
-
$672.76M(+187.7%)
$995.94M(+15.3%)
Jun 1986
$951.97M(>+9900.0%)
-$767.31M(-241.6%)
$863.62M(-47.0%)
Mar 1986
-
$542.04M(-1.2%)
$1.63B(+49.8%)
Dec 1985
-
$548.45M(+1.5%)
$1.09B(+101.5%)
Sep 1985
-
$540.44M
$540.44M
Jun 1985
$0.00(0.0%)
-
-
Jun 1984
$0.00
-
-

FAQ

  • What is GSK plc annual EBITDA?
  • What is the all-time high annual EBITDA for GSK plc?
  • What is GSK plc annual EBITDA year-on-year change?
  • What is GSK plc quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for GSK plc?
  • What is GSK plc quarterly EBITDA year-on-year change?
  • What is GSK plc TTM EBITDA?
  • What is the all-time high TTM EBITDA for GSK plc?
  • What is GSK plc TTM EBITDA year-on-year change?

What is GSK plc annual EBITDA?

The current annual EBITDA of GSK is $9.11B

What is the all-time high annual EBITDA for GSK plc?

GSK plc all-time high annual EBITDA is $19.70B

What is GSK plc annual EBITDA year-on-year change?

Over the past year, GSK annual EBITDA has changed by -$2.19B (-19.36%)

What is GSK plc quarterly EBITDA?

The current quarterly EBITDA of GSK is $4.46B

What is the all-time high quarterly EBITDA for GSK plc?

GSK plc all-time high quarterly EBITDA is $4.92B

What is GSK plc quarterly EBITDA year-on-year change?

Over the past year, GSK quarterly EBITDA has changed by +$2.61B (+140.50%)

What is GSK plc TTM EBITDA?

The current TTM EBITDA of GSK is $14.54B

What is the all-time high TTM EBITDA for GSK plc?

GSK plc all-time high TTM EBITDA is $17.83B

What is GSK plc TTM EBITDA year-on-year change?

Over the past year, GSK TTM EBITDA has changed by +$3.09B (+27.01%)
On this page